**Name of Journal: *World Journal of Diabetes***

**ESPS Manuscript NO: 27896**

**Manuscript Type: Original Article**

***Case Control Study***

**Brain-derived neurotrophic factor plasma levels and premature cognitive impairment/dementia in type 2 diabetes**

Ortiz BM *et al*. BDNF premature cognitive impairment in type 2 diabetes

**Blanca Murillo Ortiz, Joel Ramirez Emiliano, Edna Ramos Rodríguez, Sandra Martínez Garza, Hilda Macías Cervantes, Sergio Solorio Meza, Texar Alfonso Pereyra Nobara**

**Blanca Murillo Ortiz, Edna Ramos Rodríguez, Sandra Martínez Garza, Hilda Macías Cervantes, Sergio Solorio Meza, Texar Alfonso Pereyra Nobara,** Unidad de Investigación en Epidemiología Clínica, Unidad Médica de Alta Especialidad No 1, Bajio. Instituto Mexicano del Seguro Social, Guanajuato 37320, México

**Joel Ramirez Emiliano,** Departamento de Ciencias Médicas, División Ciencias de la Salud, Universidad de Guanajuato, Guanajuato 37320, México

**Author contributions:** All the authors contributed to the paper.

**Institutional review board statement:** This protocol was approved by the local bioethics committee (R-2014-1001-88).

**Informed consent statement:** The informed consent was obtained from each volunteer.

**Conflict-of-interest** **statement:** The authors declare no conflicts of interest regarding this manuscript.

**Data sharing statement:** No data were created no data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** **Blanca Murillo Ortiz, PhD,** Unidad de Investigación en Epidemiología Clínica, UMAE No. 1 Bajio, Instituto Mexicano del Seguro Social, López Mateos Esquina Insurgentes s/n Colonia Los Paraisos, León, Guanajuato 37320, México. bomo907@hotmail.com

**Telephone:** +52-477-7183039

**Fax:** +52-477-7183039

**Received:** June 21, 2016

**Peer-review started:** June 24, 2016

**First decision:** August 11, 2016

**Revised:** August 27, 2016

**Accepted:** October 1, 2016

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To assess the relationship of brain-derived neurotrophic factor (BDNF) with cognitive impairment in patients with type 2 diabetes.

***METHODS***

The study included 40 patients with diabetes mellitus type 2 (DM2), 37 patients with chronic kidney disease in hem dialysis hemodialysis therapy (HD) and 40 healthy subjects. BDNF in serum was quantified by ELISA. The Folstein Mini-Mental State Examination was used to evaluate cognitive impairment.

***RESULTS***

The patients with DM2 and the patients in HD were categorized into two groups, with cognitive impairment and without cognitive impairment. The levels of BDNF showed significant differences between patients with DM2 (43.78 ± 9.05 *vs* 31.55 ± 10.24, *P* = 0.005). There were no differences between patients in HD (11.39 ± 8.87 *vs* 11.11 ± 10.64 *P* = 0.77); interestingly, ferritin levels were higher in patients with cognitive impairment (1564 ± 1335 *vs* 664 ± 484 *P* = 0.001). The comparison of BDNF values, using a Kruskal Wallis test, between patients with DM2, in HD and healthy controls showed statistical differences (*P* < 0.001).

***CONCLUSION***

Low levels of BDNF are associated with cognitive impairment in patients with DM2. The decrease of BDNF occurs early and progressively in patients in HD.

**Key words:** Brain-derived neurotrophic factor; Diabetes mellitus type 2; Premature cognitive impairment; Hemodialysis; Folstein mini-mental

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The objective was to compare serum levels of brain-derived neurotrophic factor (BDNF) between patients with and without cognitive impairment, patients with diabetes mellitus type 2 (DM2) and chronic kidney disease patients on hemodialysis, in order to increase our knowledge on the possible role of BDNF in early cognitive impairment in DM2. We found differences in serum BDNF levels; they were lowest in patients with DM2 with cognitive impairment. In patients on hemodialysis, serum BDNF levels were lower than in patients with DM2 and healthy controls and ferritin levels were higher in patients with cognitive impairment.

Ortiz BM, Emiliano JR, Rodríguez ER, Garza SM, Cervantes HM, Meza SS, Nobara TAP. Brain-derived neurotrophic factor plasma levels and premature cognitive impairment/dementia in type 2 diabetes. *World J Diabetes* 2016; In press

**INTRODUCTION**

Brain-derived neurotrophic factor (BDNF) is a growth factor that belongs to the neurotrophin family; its mature isoform binds specifically to the tropomyosin receptor kinase B, a tyrosine kinase receptor, whereas the precursor pro-BDNF binds to the pan-neurotrophin receptor p75NTR; each mediate different neurotrophic signals[1,2]. BDNF is also important for learning and memory processes, as it induces long-term potentiation in hippocampus and structural changes in synapses.

A positive correlation between brain BDNF concentration and cognitive performance has been described, while decreased BDNF production has been proposed as one possible pathogenetic factor for Alzheimer’s disease and major depression[3,4]. Interestingly, plasma BDNF levels are decreased in patients with diabetes mellitus type 2 (DM2) and have been inversely correlated with plasma glucose and insulin resistance as assessed by homeostatic model assessment. Moreover, the output of plasma BDNF from the human brain is abrogated by hyperglycemia, but it is not regulated by hyperinsulinemia[5].

Zhen *et al*[6] found both lower serum BDNF levels and impaired cognitive functions in diabetic patients compared to controls; furthermore, a positive relationship between serum BDNF and delayed memory was observed in diabetic patients, suggesting a role for BDNF in cognitive deficit associated with DM2.

A longer duration of DM2 has been associated with a major risk of chronic kidney disease (CDK), and has been considered a possible new determinant of cognitive decline and dementia[7]. Most recent prospective studies have found an association between CKD and cognitive decline[8-11]. The Health, Aging, and Body Composition Study demonstrated that more advanced stages of CKD are associated with an increased risk for cognitive impairment[12]. BDNF plays a critical role in the functioning of the brain[13-20]. It has been observed that the concentration of serum BDNF reflects the changes in brain BDNF levels[21-23]; therefore, measuring the concentration of serum BDNF can be used to monitor its changes in the brain[24]. It was recently demonstrated that BDNF stimulates the production of prostacyclin (PGI2) in cerebral arteries[25]; it plays an important role in endothelium-dependent relaxation and has also antiplatelet, vasculoprotective, cardioprotective and anti-atherogenic properties[26-28]. Zoladz *et al*[29] demonstrated that the decrease in serum BDNF levels after hemodialysis is accompanied by elevated levels of F-isoprostanes and decreased plasma total antioxidant capacity, which might be caused by the increase in oxidative stress induced by hemodialysis.

The aim of the present study was to compare serum levels of BDNF and the results of the mini mental state examination between patients with DM2 and patients with CKD on hemodialysis, in order to obtain more information on the possible role of BDNF in premature cognitive impairment/dementia in type 2 diabetes. We also investigated whether BDNF predicted premature cognitive impairment, and if it was associated with any clinical parameters in a group of patients with chronic kidney disease.

**MATERIALS AND METHODS**

A cross-sectional study was carried out in three groups of patients from the Unidad Médica de Alta Especialidad (UMAE) No. 1 Bajío, Instituto Mexicano del Seguro Social (IMSS), León, Guanajuato, México; the patients were matched by age.

***Patients with DM2***

We selected 37 diabetic male patients, aged 39-59 year (mean age 50.57 ± 5.9 year) with a history of DM2 with a duration of 14.3 ± 6.22 year.

***Patients with chronic kidney disease on hemodialysis***

We investigated 40 men, aged 18-67 year. (mean ± SD, mean age 42.30 ± 12.8 years), with chronic kidney disease, who had started hemodialysis therapy (HD). We excluded patients older than 69 years of age and those with acute infectious diseases, psychiatric diseases or severe liver dysfunction. Baseline demographic and clinical data such as age, primary cause of renal disease and current medications were collected from the patients’ records.

***Healthy control subjects***

The control group was formed by forty healthy male volunteers from the same demographic group as the patients; they were aged 39-60 years. (mean age 42 ± 2.2 year) and received annual health examinations.

Fasting blood samples were collected from patients and healthy controls at 8 am. Serum BDNF concentrations were determined by enzyme linked immunosorbent assay (ELISA) using the Human BDNF Quantikine Kit. The concentrations of ferritin in serum and other biochemical parameters were measured at the Central Clinical Laboratory. A neurological assessment was performed before each hemodialysis session (Mini Mental).

The study was performed in accordance with the Declaration of Helsinki of the World Medical Association and was approved by the local Bioethics Committee of the Unidad Médica de Alta Especialidad (UMAE) No. 1 Bajío, Instituto Mexicano del Seguro Social (IMSS), León, Guanajuato, México. All patients signed an informed consent form for this investigation.

***Statiscal analysis***

The statistical analysis was performed using Microsoft Excel and Statistica software. The statistical significance of the differences observed between patients and controls was assessed using two-tailed t-test, Chi square and Kruskal-Wallis (*P* < 0.05).

**RESULTS**

The patients with DM2 and on hemodialysis were categorized according to the score obtained in the Folstein Mini-Mental State Examination into a group with cognitive impairment and a group without cognitive impairment. The group of patients with type 2 diabetes and cognitive impairment had 19 patients and the group without cognitive impairment had 18 patients. The average age was 50.57 ± 5.9 years with a history of type 2 diabetes mellitus with a duration of 14.3 ± 6.22 years. We were able to analyze the differences between patients with and without cognitive impairment (Table 1). We observed significant differences in the levels of glycated Hb, which were higher in patients with cognitive impairment (8.36 ± 1.52 *vs* 7.33 ± 1.42 *P* = 0.02). There were also differences in the duration of diabetes; patients with cognitive impairment had more years of DM2 (14.31 ± 6.22 *vs* 9.05 ± 4.64 *P* = 0.007). The values ​​of serum BDNF also showed significant differences between patients with and without cognitive impairment (31.55 ± 10.24 *vs* 43.78 ± 9.05 *P* = 0.005).

The group of patients on HD with cognitive impairment had 17 patients; the group without cognitive impairment had 23 patients. The average age of the patients was 42.30 ± 12.8 years. The most common cause of renal failure was diabetes mellitus (45%), followed by glomerulonephritis (20%), renal hypoplasia (15%), hypertension (10%) and other causes (10%). Sixty-five point seven percent of the patients had been subjected to a vascular access procedure using a catheter, while only 31.2% had an arteriovenous fistula. There were also significant differences in patients with chronic renal disease on replacement therapy with hemodialysis between those with and without cognitive impairment (Table 2). Ferritin levels were higher in patients with cognitive impairment (1564 ± 1335 *vs* 664 ± 484 *P* = 0.001), in contrast to serum levels of BDNF (11.39 ± 8.87 *vs* 11.11 ± 10.64 *P* = 0.77); however, both groups of patients on hemodialysis had lower levels than healthy controls.

The serum BDNF levels of healthy control subjects were 39.36 ± 8.9 ng/mL. The comparison of BDNF levels, using a Kruskal Wallis test, between patients with DM2, HD and healthy controls showed statistically significant differences (*P* < 0.001) Figure 1.

**DISCUSSION**

Most recent prospective studies associate chronic kidney disease with cognitive impairment. There has been a significant increase in the prevalence of chronic degenerative diseases worldwide; thus, there is a particular interest in learning how to modify the conditions that cause cognitive decline and dementia. DM2 has been strongly associated with an increased loss of cognitive functions. A recent cohort study showed that high glucose levels may be a risk factor for dementia and that the combination of DM2 and hypertension greatly increase the risk of cognitive impairment. Beside vascular factors, other risk factors include the formation of advanced glycosylation products, oxidative inflammation and stress, alterations in the hypothalamic-pituitary-adrenal axis and cortisol levels[30], and abnormalities in insulin secretion and signaling that promote cerebral amyloidosis.

The analysis of the relationship between serum ferritin and ​​Mini-Mental scores in HD patients showed a significant difference between serum ferritin levels and the presence of cognitive impairment according to the Folstein test. Therefore, we can say that a higher iron overload corresponds to greater cognitive impairment.

Becerril-Ortega *et al*[31] analyzed the relationship between iron and neurodegenerative diseases (especially Alzheimer’s disease) that affect cognitive impairment in a transgenic mouse model; they observed that iron interferes with the processing of the amyloid precursor protein (APP), neuronal signaling and cognitive behavior. The proposed mechanism is that iron overload increases the production of amyloidogenic KPI-APP and amyloid beta; this is mediated by N-methyl-D-aspartate receptors (NMDAR), mainly GluN2B, which is overexpressed. These data suggest that the damage induced by iron overload through APP accelerates cognitive impairment due to excessive extrasynaptic NMDAR activity 30, causing a significant memory and learning deficit, and inhibiting synaptic plasticity, mitochondrial dysfunction and neuronal apoptosis, which can lead to neurodegeneration.

This is also supported by a study that showed evidence of iron overload in brain structures such as the putamen, dentate nucleus, substantia nigra and red nucleus of patients with beta-thalassemia[32]. Another group of patients with thalassemia also showed iron overload and increased oxidative damage[33]. Blasco *et al*[34] found a significant positive association between obesity, insulin resistance and iron overload in the caudate nucleus, hypothalamus and hippocampus, and poor cognitive performance. Furthermore, it has been shown that iron overload causes oxidative stress *in vitro*[35] and can affect the hematopoiesis of bone marrow in mice by increasing oxidative stress[36].

Although there are multiple factors that influence cognitive impairment, several studies have shown an association with circulating levels of BDNF[37,38], and have suggested a synergistic effect between the presence of dementia and BDNF levels in in DM2[39]. Our study found this association and also that patients on HD had increased oxidative stress, probably induced by iron overload, which was evidenced by elevated levels of ferritin. This was significantly associated with greater cognitive impairment and with serum BDNF levels well below the levels found in patients with type 2 diabetes mellitus and healthy controls.

One of the most common advanced complications of DM2 is CKD. The progressive loss of renal function could make it necessary for the patient to receive renal replacement therapy such as hemodialysis, and the progressive loss of circulating levels of BDNF should be prevented in patients with DM2 to avoid premature cognitive decline. There have been several experimental studies with curcumin[40] and resveratrol, both of which increase serum BDNF levels. Curcumin has an antidepressant effect, mediated by its antioxidant activity and up-regulation of phosphor Akt and mTOR levels in the hippocampus and prefrontal cortex[41]. Resveratrol has antidepressant-like effects, mediated in part by the normalization of serum corticosterone levels and the up-regulation of Perk, pCREB and BDNF levels in the hippocampus and amygdala[42]. This is an alternative that should be investigated further in future randomized clinical trials.

**COMMENTS**

***Background***

Diabetes mellitus type 2 (DM2) has been strongly associated with an increased loss of cognitive functions, while decreased brain-derived neurotrophic factor (BDNF) production has been proposed as one possible pathogenetic factor for premature cognitive impairment/dementia. A longer duration of DM2 has been associated with a major risk of chronic kidney disease (CDK), and has been considered a possible new determinant of cognitive decline and dementia.

***Research frontiers***

The analysis of the relationship between serum ferritin and ​​Mini-Mental scores in hemodialysis therapy (HD) patients showed a significant difference between serum ferritin levels and the presence of cognitive impairment according to the Folstein test. Therefore, we can say that a higher iron overload corresponds to greater cognitive impairment, and it is of interest which factors modify the decrement of BDNF production. Measuring the concentration of serum BDNF can be used to monitor its changes in the brain, in order to influence the course of the disease.

***Innovations and breakthroughs***

The authors confirm the serum BDNF levels between patients with DM2, HD and healthy controls showed statistically significant differences. Ferritin levels were higher in patients in HD with cognitive impairment, is a breakthrough in the understanding of the factors contributing to the loss of BDNF and cognitive impairment.

***Applications***

Monitoring levels of BDNF can prevent cognitive decline implementing new measures such as the use of antioxidants proposed recently and currently under research.

***Peer-review***

The study is original and evaluates the cognitive impairment in diabetes mellitus in relationship with the brain-derived neurotrophic factor plasma levels and ferritin. The article has interest and likes suitable for the publication in the Journal.

**REFERENCES**

1 **Cohen-Cory S**, Kidane AH, Shirkey NJ, Marshak S. Brain-derived neurotrophic factor and the development of structural neuronal connectivity. *Dev Neurobiol* 2010; **70**: 271-288 [PMID: 20186709 DOI: 10.1002/dneu.20774]

2 **Zoladz JA**, Pilc A. The effect of physical activity on the brain derived neurotrophic factor: from animal to human studies. *J Physiol Pharmacol* 2010; **61**: 533-541 [PMID: 21081796]

3 **Peng S**, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. *J Neurochem* 2005; **93**: 1412-1421 [PMID: 15935057 DOI: 10.1111/j.1471-4159.2005.]

4 **Connor B**, Young D, Yan Q, Faull RL, Synek B, Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. *Brain Res Mol Brain Res* 1997; **49**: 71-81 [PMID: 9387865]

5 **Chaldakov GN**, Tonchev AB, Manni L, Hristova MG, Nikolova V, Fiore M, Vyagova D, Peneva VN, Aloe L. Comment on: Krabbe KS, Nielsen AR, Krogh-Madsen R et al (2007) Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 50: 431-438. *Diabetologia* 2007; **50**: 1781-1782 [PMID: 17546439 DOI: 10.1007/s00125-007-0706-0]

6 **Zhen YF**, Zhang J, Liu XY, Fang H, Tian LB, Zhou DH, Kosten TR, Zhang XY. Low BDNF is associated with cognitive deficits in patients with type 2 diabetes. *Psychopharmacology (Berl)* 2013; **227**: 93-100 [PMID: 23263460 DOI: 10.1007/s00213-012-2942-3]

7 **Khatri M**, Nickolas T, Moon YP, Paik MC, Rundek T, Elkind MS, Sacco RL, Wright CB. CKD associates with cognitive decline. *J Am Soc Nephrol* 2009; **20**: 2427-2432 [PMID: 19729443 DOI: 10.1681/ASN.2008101090]

8 **Buchman AS**, Tanne D, Boyle PA, Shah RC, Leurgans SE, Bennett DA. Kidney function is associated with the rate of cognitive decline in the elderly. *Neurology* 2009; **73**: 920-927 [PMID: 19657107 DOI: 10.1212/WNL.0b013e3181b72629]

9 **Sasaki Y**, Marioni R, Kasai M, Ishii H, Yamaguchi S, Meguro K. Chronic kidney disease: a risk factor for dementia onset: a population-based study. The Osaki-Tajiri Project. *J Am Geriatr Soc* 2011; **59**: 1175-1181 [PMID: 21668914 DOI: 10.1111/j.1532-5415.2011.03477.x]

10 **Davey A**, Elias MF, Robbins MA, Seliger SL, Dore GA. Decline in renal functioning is associated with longitudinal decline in global cognitive functioning, abstract reasoning and verbal memory. *Nephrol Dial Transplant* 2013; **28**: 1810-1819 [PMID: 23166308 DOI: 10.1093/ndt/gfs470]

11 **Darsie B**, Shlipak MG, Sarnak MJ, Katz R, Fitzpatrick AL, Odden MC. Kidney function and cognitive health in older adults: the Cardiovascular Health Study. *Am J Epidemiol* 2014; **180**: 68-75 [PMID: 24844846 DOI: 10.1093/aje/kwu102]

12 **Kurella M**, Chertow GM, Fried LF, Cummings SR, Harris T, Simonsick E, Satterfield S, Ayonayon H, Yaffe K. Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. *J Am Soc Nephrol* 2005; **16**: 2127-2133 [PMID: 15888561 DOI: 10.1681/ASN.2005010005]

13 **Binder DK**, Scharfman HE. Brain-derived neurotrophic factor. *Growth Factors* 2004; **22**: 123-131 [PMID: 15518235]

14 **Monteggia LM**, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T, Meuth S, Nagy A, Greene RW, Nestler EJ. Essential role of brain-derived neurotrophic factor in adult hippocampal function. *Proc Natl Acad Sci USA* 2004; **101**: 10827-10832 [PMID: 15249684 DOI: 10.1073/pnas.0402141101]

15 **McAllister AK**, Katz LC, Lo DC. Neurotrophins and synaptic plasticity. *Annu Rev Neurosci* 1999; **22**: 295-318 [PMID: 10202541 DOI: 10.1146/annurev.neuro.22.1.295]

16 **Figurov A**, Pozzo-Miller LD, Olafsson P, Wang T, Lu B. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. *Nature* 1996; **381**: 706-709 [PMID: 8649517 DOI: 10.1038/381706a0]

17 **Kafitz KW**, Rose CR, Thoenen H, Konnerth A. Neurotrophin-evoked rapid excitation through TrkB receptors. *Nature* 1999; **401**: 918-921 [PMID: 10553907 DOI: 10.1038/44847]

18 **Alonso M**, Vianna MR, Izquierdo I, Medina JH. Signaling mechanisms mediating BDNF modulation of memory formation in vivo in the hippocampus. *Cell Mol Neurobiol* 2002; **22**: 663-674 [PMID: 12585686]

19 **Kossel AH**, Cambridge SB, Wagner U, Bonhoeffer T. A caged Ab reveals an immediate/instructive effect of BDNF during hippocampal synaptic potentiation. *Proc Natl Acad Sci USA* 2001; **98**: 14702-14707 [PMID: 11724927 DOI: 10.1073/pnas.251326998]

20 **Lee JL**, Everitt BJ, Thomas KL. Independent cellular processes for hippocampal memory consolidation and reconsolidation. *Science* 2004; **304**: 839-843 [PMID: 15073322 DOI: 10.1126/science.1095760]

21 **Karege F**, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. *Neurosci Lett* 2002; **328**: 261-264 [PMID: 12147321]

22 **Sartorius A**, Hellweg R, Litzke J, Vogt M, Dormann C, Vollmayr B, Danker-Hopfe H, Gass P. Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. *Pharmacopsychiatry* 2009; **42**: 270-276 [PMID: 19924587 DOI: 10.1055/s-0029-1224162]

23 **Blugeot A**, Rivat C, Bouvier E, Molet J, Mouchard A, Zeau B, Bernard C, Benoliel JJ, Becker C. Vulnerability to depression: from brain neuroplasticity to identification of biomarkers. *J Neurosci* 2011; **31**: 12889-12899 [PMID: 21900567 DOI: 10.1523/JNEUROSCI.1309-11.2011]

24 **Nakahashi T**, Fujimura H, Altar CA, Li J, Kambayashi J, Tandon NN, Sun B. Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. *FEBS Lett* 2000; **470**: 113-117 [PMID: 10734218]

25 **Santhanam AV**, Smith LA, Katusic ZS. Brain-derived neurotrophic factor stimulates production of prostacyclin in cerebral arteries. *Stroke* 2010; **41**: 350-356 [PMID: 20019327 DOI: 10.1161/STROKEAHA.109.564492]

26 **Gryglewski RJ**. Prostaglandins, platelets, and atherosclerosis. *CRC Crit Rev Biochem* 1980; **7**: 291-338 [PMID: 6771102]

27 **Grosser T**, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. *J Clin Invest* 2006; **116**: 4-15 [PMID: 16395396 DOI: 10.1172/JCI27291]

28 **Chlopicki S**, Swies J, Mogielnicki A, Buczko W, Bartus M, Lomnicka M, Adamus J, Gebicki J. 1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway. *Br J Pharmacol* 2007; **152**: 230-239 [PMID: 17641676 DOI: 10.1038/sj.bjp.0707383]

29 **Zoladz JA**, Śmigielski M, Majerczak J, Nowak ŁR, Zapart-Bukowska J, Smoleński O, Kulpa J, Duda K, Drzewińska J, Bartosz G. Hemodialysis decreases serum brain-derived neurotrophic factor concentration in humans. *Neurochem Res* 2012; **37**: 2715-2724 [PMID: 22903469 DOI: 10.1007/s11064-012-0862-6]

30 **Passaro A**, Dalla Nora E, Morieri ML, Soavi C, Sanz JM, Zurlo A, Fellin R, Zuliani G. Brain-derived neurotrophic factor plasma levels: relationship with dementia and diabetes in the elderly population. *J Gerontol A Biol Sci Med Sci* 2015; **70**: 294-302 [PMID: 24621946 DOI: 10.1093]

31 **Becerril-Ortega J**, Bordji K, Fréret T, Rush T, Buisson A. Iron overload accelerates neuronal amyloid-β production and cognitive impairment in transgenic mice model of Alzheimer's disease. *Neurobiol Aging* 2014; **35**: 2288-2301 [PMID: 24863668 DOI: 10.1016/j.neurobiolaging.2014.04.019]

32 **Qiu D**, Chan GC, Chu J, Chan Q, Ha SY, Moseley ME, Khong PL. MR quantitative susceptibility imaging for the evaluation of iron loading in the brains of patients with β-thalassemia major. *AJNR Am J Neuroradiol* 2014; **35**: 1085-1090 [PMID: 24578278 DOI: 10.3174/ajnr.A3849]

33 **Karakas Z**, Yilmaz Y, Celik DD, Annayev A, Demirel S, Kuruca SE. Total oxidant and antioxidant capacity in patients with transfusion dependent and nondependent beta thalassemia. Proceedings of the 57th ASH Annual Meeting Abstracts, 2015 Dec Vol 126, Issue 23: 4573

34 **Blasco G**, Puig J, Daunis-I-Estadella J, Molina X, Xifra G, Fernández-Aranda F, Pedraza S, Ricart W, Portero-Otín M, Fernández-Real JM. Brain iron overload, insulin resistance, and cognitive performance in obese subjects: a preliminary MRI case-control study. *Diabetes Care* 2014; **37**: 3076-3083 [PMID: 25125507 DOI: 10.2337/dc14-0664]

35 **Lu WY**, Zhao MF, Chai X, Meng JX, Xie F, Mu J, Zhu HB, Xu XN, Xiao X, Deng Q, Ma L. Iron Overload Impairs Hematopoiesis by Damaging MSCs Through ROS Signaling Pathway. Proceedings of the 54th ASH Annual Meeting Abstracts, 2012 Nov 16, Vol 120, Issue 21: 92-5172

36 **Chai X**, Li D, Cao X, Zhang Y, Mu J, Lu W, Xiao X, Li C, Meng J, Chen J, Li Q, Wang J, Meng A, Zhao M. ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice. *Sci Rep* 2015; **5**: 10181 [PMID: 25970748 DOI: 10.1038/srep10181]

37 **Ono M**, Ichihara J, Nonomura T, Itakura Y, Taiji M, Nakayama C, Noguchi H. Brain-derived neurotrophic factor reduces blood glucose level in obese diabetic mice but not in normal mice. *Biochem Biophys Res Commun* 1997; **238**: 633-637 [PMID: 9299565 DOI: 10.1006/bbrc.1997.7220]

38 **Ott A**, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. *Neurology* 1999; **53**: 1937-1942 [PMID: 10599761]

39 **Gregg EW**, Yaffe K, Cauley JA, Rolka DB, Blackwell TL, Narayan KM, Cummings SR. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. *Arch Intern Med* 2000; **160**: 174-180 [PMID: 10647755]

40 **Franco-Robles E**, Campos-Cervantes A, Murillo-Ortiz BO, Segovia J, López-Briones S, Vergara P, Pérez-Vázquez V, Solís-Ortiz MS, Ramírez-Emiliano J. Effects of curcumin on brain-derived neurotrophic factor levels and oxidative damage in obesity and diabetes. *Appl Physiol Nutr Metab* 2014; **39**: 211-218 [PMID: 24476477 DOI: 10.1139/apnm-2013-0133]

41 **Liu D**, Wang Z, Gao Z, Xie K, Zhang Q, Jiang H, Pang Q. Effects of curcumin on learning and memory deficits, BDNF, and ERK protein expression in rats exposed to chronic unpredictable stress. *Behav Brain Res* 2014; **271**: 116-121 [PMID: 24914461 DOI: 10.1016/j.bbr.2014.05.068]

42 **Liu D**, Xie K, Yang X, Gu J, Ge L, Wang X, Wang Z. Resveratrol reverses the effects of chronic unpredictable mild stress on behavior, serum corticosterone levels and BDNF expression in rats. *Behav Brain Res* 2014; **264**: 9-16 [PMID: 24503118 DOI: 10.1016/j.bbr.2014.01.039]

**P-Reviewer:** Gómez-Sáez JM, Li P, Tziomalos K **S-Editor:** Qiu S **L-Editor: E-Editor:**

**Table 1 Clinical characteristics of hemodialysis patients**

|  |  |  |  |
| --- | --- | --- | --- |
| **Baseline characteristics**  | **HD patients with cognitive impairment (*n* = 17)**  | **HD patients without cognitive impairment****(*n* = 23)**  | ***P*** |
| Age (yr) | 51.88 ± 12.81 | 42.30 ± 12.87 | 0.02 |
| Duration of hemodialysis (mon) | 41.29 ± 42.01 | 32.08 ± 36-76 | 0.13 |
| BDNF (ng/mL) | 11.39 ± 8.87 | 11.11 ± 10.64 | 0.77 |
| Creatinine (mg/dL) | 8.90 ± 1.90 | 9.21 ± 2.61 | 0.68 |
| Urea (mg/dL) | 128.68 ± 54.23 | 127.74 ± 51.54 | 0.77 |
| Hemoglobin (g/dL) | 12.13 ± 1.38 | 11.53 ± 1.92 | 0.51 |
| Ferritin (ng/mL) | 1564 ± 1335.05 | 664.22 ± 484.99 | 0.001 |
| Mini-mental state examination  | 19.58 ± 3.24 | 26.08 ± 1.50 | 0.0001 |

BDNF: Brain-derived neurotrophic factor; HD: Hemodialysis therapy.

**Table 2 Clinical characteristics of diabetes mellitus type 2 patients**

|  |  |  |  |
| --- | --- | --- | --- |
| **Baseline characteristics** | **DM2 patients with cognitive impairment (*n* = 19)** | **DM2 patients without cognitive impairment (*n* = 18)** | ***P*** |
| Age (yr) | 50.57 ± 5.90 | 54.05 ± 3.63 | 0.06 |
| Duration of DM2 (yr) | 14.31 ± 6.22 | 9.05 ± 4.64  | 0.007 |
| BDNF (ng/mL) | 31.55 ± 10.24 | 43.78 ± 9.05 | 0.005 |
| Glucose (mg/dL) | 177 ± 64.91 | 138 ± 43.90 | 0.07 |
| Glycated hemoglobin (HBA1c) (%) | 8.36 ± 1.52 | 7.33 ± 1.42  | 0.02 |
| Minimental state examination | 20.26 ± 2.15  | 25.44 ± 1.50  | 0.0001 |

BDNF: Brain-derived neurotrophic factor; DM2: Diabetes mellitus type 2.

P < 0.001

**Figure 1 Difference between serum brain-derived neurotrophic factor levels between control subjects and patients in hemodialysis therapy patients with diabetes mellitus type 2.** BDNF: Brain-derived neurotrophic factor; HD: Hemodialysis therapy; DM2: Diabetes mellitus type 2.